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AbSTrACT
Globally, non- steroidal anti- inflammatory drugs 
(NSAIDs) are highly used to treat pain. With the rise of 
the COVID-19 pandemic, the safety of NSAIDs use has 
been called into question. These concerns are worthy of 
review. At present, there is no compelling data showing 
that NSAIDs worsen the severity of COVID-19 symptoms 
or increase one’s likelihood of contracting the illness. 
For patients in pain and without symptoms that could 
potentially be attributed to COVID-19 (cough, fevers/
chills, lethargy, myalgias, anosmia and so on), NSAIDs 
should continue to remain a viable option to provide 
analgesia to patients in need.
InTroduCTIon
Globally, non- steroidal anti- inflammatory drugs 
(NSAIDs) are the most commonly used medica-
tions for the treatment of acute and chronic pain. 
With appropriate patient selection and dosing, 
these medications have served as a cornerstone of 
the pharmacologic toolbox to treat pain since the 
1800s.1 While NSAIDs can provide significant anal-
gesia to patients in pain, this class of medications 
carries risks including cardiovascular dysfunction, 
bleeding, gastrointestinal upset and kidney injury.2 
With the rise of the current coronavirus disease 
2019 (COVID-19) global pandemic caused by the 
spread of the severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2), questions have 
arisen regarding the safety of NSAIDs during this 
period of uncertainty on how to best respond to 
this novel disease. An assessment of the current 
sources of concern surrounding NSAID use during 
the pandemic can offer insight on their risk–benefit 
profile for the treatment of pain at the present time.
dISCuSSIon
The concern regarding NSAID use during the 
pandemic was first published by three European 
physicians and scientists in a letter to the editor 
of the journal The Lancet Respiratory Medi-
cine on 11 March 2020.3 While these authors 
wrote primarily about hypertension and diabetes 
mellitus as risk factors for contracting COVID-
19, they briefly commented that ibuprofen could 
increase levels of cellularly expressed ACE2. This 
is potentially concerning as SARS- CoV-2 infects 
cells by binding to ACE2, which is commonly 
expressed in tissues of the cardiovascular, gastro-
intestinal and renal systems.4 However, some 
concerns raised in this letter are observational and 
have yet to be proven. Furthermore, the authors 
of this letter do not cite a source for their asser-
tion that ibuprofen can increase levels of ACE2. 
During our literature search on PubMed for this 
article, we could not identify research to support 
this. The uncertainty surrounding the origin 
of this claim was also examined in an article in 
Chemical & Engineering News, a trade magazine 
published by the American Chemical Society.5 
They report that the authors of the letter in The 
Lancet did not offer specific clarification when 
asked for evidence showing that ibuprofen actu-
ally increases ACE2 expression.
More widespread attention regarding NSAID use 
was garnered by a tweet from the Health Minister 
of France on 14 March 2020. Oliver Veran advised 
against using medications like ibuprofen and 
cortisone and recommended the use of acetamin-
ophen (paracetamol) in patients with COVID-19. 
There was no specific data referenced to support 
his recommendation.6 His comments appear to 
have resulted from media reports of four cases of 
younger patients in France with COVID-19 who 
took ibuprofen for their symptoms and went on 
to have worsening symptoms.7 No demographic 
or descriptive information about these patients 
has been published, and the timing and dosing of 
ibuprofen in relation to their COVID-19 symptoms 
are not known.
Following this, several health and governmental 
groups issued commentary on this subject. The 
WHO initially recommended that ibuprofen use 
should be avoided for symptoms of COVID-19. 
They then reversed that recommendation on 18 
March 2020 stating, ‘based on currently available 
information, WHO does not recommend against the 
use of ibuprofen’.8 The European Medical Agency, 
also on 18 March 2020, stated, ‘there is currently 
no scientific evidence establishing a link between 
ibuprofen and worsening of COVID-19’.9 This 
organization did comment that there is evidence 
that NSAIDs could contribute to a more severe 
course of chickenpox and some bacterial infections. 
It also suggested that acetaminophen (paracetamol) 
was generally the preferred agent for fever and pain 
during an infectious illness and called for further 
research on the impact of NSAID use in patients 
with COVID-19. On 19 March 2020, the US Food 
and Drug Administration issued a statement that 
it was ‘not aware of scientific evidence connecting 
the use of NSAIDs, like ibuprofen, with worsening 
COVID-19 symptoms’.10 On 19 April 2020, the 
WHO released a scientific brief to address NSAID 
use in patients with COVID-19.11 While they note 
the limitation of a current lack of studies directly 
examining NSAID use in patients with COVID-19, 
their review included 73 relevant published studies. 
After examining these studies, the WHO found no 
evidence to suggest that NSAID use in patients with 
COVID-19 results in significant adverse events or 
increased mortality.
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An article examining the impact of NSAID use in patients with 
COVID-19 noted that while there is evidence that NSAIDs can 
worsen outcomes in patients with respiratory infections, there is 
no strong signal yet detected to show this occurs in patients with 
COVID-19. However, the author notes that there are potential 
risks associated with using NSAIDs in patients without infection 
including heart attacks, stroke and kidney injury. The author 
suggests these risks could be increased if fever and dehydration 
occur due to an infection like COVID-19. Given the potential 
risks, the author concluded that NSAIDs should likely not be 
first- line treatment for fever and pain in patients with COVID-
19.12 However, a recent review article that also examines poten-
tial connections between NSAIDs and COVID-19 noted that 
studies examining ibuprofen’s connection with the outcomes 
of respiratory illnesses are often at risk of different types of 
biases.13 Potential biases include the risk of assuming a causality 
between ibuprofen administration and a disease’s natural course 
of severity when they may not be related (protopathic bias) 
and also the risk of selection bias where NSAIDs may not be 
used unless more severe symptoms are present. Additionally, 
many patients who take NSAIDs chronically for pain have other 
chronic medical conditions that can increase their risk profile for 
poorer COVID-19 outcomes compared with otherwise healthy 
patients—making attempts to correlate NSAID use with respira-
tory illness outcomes a challenging endeavor. It should be noted 
that many studies examining NSAIDs and respiratory infection 
outcomes focus on bacterial rather than viral illnesses. One retro-
spective study from 2016 examined NSAID use in H1N1 influ-
enza patients and found ‘no compelling evidence’ that NSAID 
use increased mortality in these patients.14 Interestingly, a recent 
prospective trial of hospitalized patients with influenza found 
that the use of naproxen, in conjunction with other medications, 
actually yielded a mortality benefit.15
ConCluSIon
While an absence of evidence regarding NSAIDs interplay with 
the manifestation of COVID-19 symptoms and subsequent 
severity of illness does not necessarily equate to evidence of 
absence, the current state of the data surrounding this claim 
must be considered when currently treating patients. At present, 
we cannot locate any data showing that ibuprofen worsens 
the severity of COVID-19 symptoms or increases one’s like-
lihood of contracting the illness. Similarly, in a recent article 
by a fellow pain medicine physician in Italy, no link between 
NSAIDs and COVID-19 could be found in the published litera-
ture.16 Furthermore, the present concerns that have been raised 
regarding NSAIDs have been specific for their use in patients 
with COVID-19 symptoms, not asymptomatic patients who 
otherwise have pain that needs to be treated.
At this time, there is no reason to remove NSAIDs as an option 
for treating appropriate patients in pain, especially if they are 
without possible or confirmed COVID-19 symptoms. The pres-
ence of a pandemic does not alter the baseline risks of NSAIDs 
use, which should be avoided or used with caution in several 
situations including when treating patients who have renal or 
cardiovascular disease or advanced age. That said, no pharmaco-
logic treatment for pain is without risks, and other options have 
been associated with worsening immune function. For example, 
the role of opioids functioning as an immunosuppressant have 
been well documented.17–19 Thus, it appears reasonable for 
patients who take NSAIDs chronically to continue to do so and 
to continue to use this class of medication judiciously to treat 
acute pain as well. However, until more data arises, it would be 
reasonable, out of an abundance of caution, to avoid NSAID use 
in patients who have possible symptoms of, or recent high- risk 
exposures to, COVID-19.
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